Registered Office: 904, Shapath-1, Opp. Rajpath Club, S. G. Highway, Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541 E-mail: info@kamronlabs.com Website: www.kamronlabs.com

CIN: L24231GJ1988PLC010956



15th September, 2020

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

Sub: Submission of Unaudited Financial Results for the Quarter ended on 30th June, 2020

Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 30^{th} June, 2020.

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 30th June, 2020 along with Limited Review Report thereon.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

For KAMRON LABORATORIES LIMITED

FOR, KAMRON LABORATORIES LTD.

KAMLESH J. LASKARI MANAGING DIRECTOR (DIN: 00461198)

Encl: As above.

Samble 1 landen



Registered Office: 904, Shapath-1, Opp. Rajpath Club, S. G. Highway, Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541 CIN: L24231GJ1988PLC010956



STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2020

(Rs. In lakh)

Particulars		(Previous Year ended on		
		30-06-2020	31-03-2020	30-06-2019	31-03-2020
(Refer Notes Below)		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	136.21	137.09	158.51	659.13
2	Other income	0.00	0.63	0.51	2.34
3	Total Income (1+2)	136.21	137.72	159.02	661.47
4	Expenses				
	a. Cost of Materials consumed		-	0.63	54.43
	b. Purchases of stock-in-trade	58.20	46.00	88.84	270.14
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	13.62	(26.23)	18.09	162.94
	d. Employee benefits expense	28.56	75.39	36.50	194.49
	e. Finance costs	0.24	1.78	0.02	2.02
	f. Depreciation & amortisation expense	28.66	(4.45)	20.86	42.26
	g. Other expenses	32.97	98.82	54.54	310.28
	Total Expenses	162.25	191.31	219.48	1036.56
5	Profit / (Loss) before exceptional items and tax (3-4)	(26.04)	(53.59)	(60.46)	(375.09)
6	Exceptional items	0.00	0.77	-	24.34
7	Profit / (Loss) before tax (5-6)	(26.04)	(52.82)	(60.46)	(350.75)
8	Tax expense:				
	Current tax		-	-	25
	Deferred tax		-	**	0.71
9	Profit (Loss) for the period from continuing operations (7-8)	(26.04)	(52.82)	(60.46)	(376.46)
10	Profit/(loss) from discontinuing operations before Tax		-	-	
11	Tax expense of discontinuing operations	-	-	7.0	
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	
13	Profit / (Loss) for the period (9+12)	(26.04)	(52.82)	(60.46)	(376.46)



FOR, KAMRON LABORATORIES LTD. 1 Cankan

Kambul 1 MANAGING DIRECTOR

Registered Office: 904, Shapath-1, Opp. Rajpath Club, S. G. Highway, Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541 E-mail: info@kamronlabs.com Website: www.kamronlabs.com CIN: L24231GJ1988PLC010956



	Particulars	3 months ended on			Previous Year ended on
		30-06-2020 (Unaudited)	31-03-2020 (Audited)	30-06-2019 (Unaudited)	31-03-2020 (Audited)
14	Other Comprehensive Income				
	Items that will not be reclassified subsequently to profit or loss	-	-	-	-
	Mention Item				
	Mention Item				
	Mention Item				
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	Items that will be reclassified subsequently to profit or loss	+	-	-	-
	Mention Item				
	Mention Item				
	Mention Item				
	Income tax relating to items that will be reclassified to profit or loss		-	-	
	Other Comprehensive Income, net of tax		-	-	
15	Total Comprehensive Income for the period (13+14)	(26.04)	(52.82)	(60.46)	(376.46)
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	585.00	585.00	585.00	585.00
17	Reserves excluding Revaluation Reserves				
18	Earnings Per Share of Rs. 10/- each (for continuing operations)				
	- Basic	(0.04)	(0.90)	(1.03)	(6.45)
	- Diluted	(0.04)	(0.90)	(1.03)	(6.45)
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)				
	- Basic		-	-	
	- Diluted		:=	-	
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)				
	- Basic	(0.04)	(0.90)	(1.03)	(6.45)
	- Diluted	(0.04)	(0.90)	(1.03)	(6.45)



FOR, KAMRON LABORATORIES LTD. 1 Carleen. MANAGING DIRECTOR

Registered Office: 904, Shapath-1, Opp. Rajpath Club, S. G. Highway, Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541 E-mail: info@kamronlabs.com Website: www.kamronlabs.com

CIN: L24231GJ1988PLC010956



Notes:

1	The Company is operating only in two segment i.e. Marketing of pharmaceutical products and Nutraceuticals and Dietary supplements.				
2	The Company does not have any subsidiary / associate.				
3	Provision for taxation/deferred taxation, if any, will be made at the year end.				
4	Figures, wherever required, are regrouped / rearranged.				
5	The above results have been reviewed by audit committee and approved by Board of Directors of Company at it meeting held on 15th September, 2020.				
6	The figures for quarter ended on 31st March, 2020 are the balancing figures between the audited figures in respect of the full financial year ended on 31st March, 2020 and the year to date figures up to the third quarter of the financial year 2019-20.				

For KAMRON LABORATORIES LIMITED FOR, KAMRON LABORATORIES LTD.

auntuch 1

Carrey MANAGRAMITESHO. LASKARI MANAGING DIRECTOR

(DIN:00461198)

Date: 15th September, 2020

Place: Ahmedabad





CHARTERED ACCOUNTANTS



LIMITED REVIEW REPORT

Review report to Board of Directors of Kamron Laboratories Ltd

We have reviewed the accompanying statement of unaudited standalone financial results of Kamron Laboratories Ltd for the period ended 30th June 2020, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

AHMEDAB

For M/s Rangwala & Co. Chartered Accountants

(Firm's Registration No. 115833W)

Partner

(Membership No.031268) (UDIN: 20031268AAAABF8112

Date:15/09/2020 Place:Ahmedabad